Business Description
Curis Inc
NAICS : 325414
SIC : 2836
ISIN : US2312692005
Description
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.69 | |||||
| Equity-to-Asset | -0.17 | |||||
| Debt-to-Equity | -0.4 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -47.28 | |||||
| Beneish M-Score | -3.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.4 | |||||
| 3-Year EBITDA Growth Rate | 8.8 | |||||
| 3-Year EPS without NRI Growth Rate | 11.7 | |||||
| 3-Year FCF Growth Rate | 8.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 39.95 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 29.69 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.55 | |||||
| 9-Day RSI | 42.07 | |||||
| 14-Day RSI | 45.69 | |||||
| 3-1 Month Momentum % | 68.49 | |||||
| 6-1 Month Momentum % | -19.61 | |||||
| 12-1 Month Momentum % | -61.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.23 | |||||
| Quick Ratio | 1.23 | |||||
| Cash Ratio | 1.01 | |||||
| Days Sales Outstanding | 86.95 | |||||
| Days Payable | 20241.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.8 | |||||
| Shareholder Yield % | -98.64 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.42 | |||||
| Operating Margin % | -376.99 | |||||
| Net Margin % | -376.09 | |||||
| EBITDA Margin % | -359.44 | |||||
| FCF Margin % | -299.79 | |||||
| ROA % | -89.45 | |||||
| ROIC % | -170.9 | |||||
| 3-Year ROIIC % | 12.33 | |||||
| ROC (Joel Greenblatt) % | -1171.86 | |||||
| ROCE % | -140.83 | |||||
| Moat score | 3 | |||||
| Tariff score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.04 | |||||
| EV-to-EBIT | -0.12 | |||||
| EV-to-Forward-EBIT | -0.12 | |||||
| EV-to-EBITDA | -0.12 | |||||
| EV-to-Forward-EBITDA | -0.12 | |||||
| EV-to-Revenue | 0.43 | |||||
| EV-to-Forward-Revenue | 0.44 | |||||
| EV-to-FCF | -0.14 | |||||
| Price-to-GF-Value | 0.19 | |||||
| Price-to-Median-PS-Value | 0.14 | |||||
| Earnings Yield (Greenblatt) % | -833.33 | |||||
| FCF Yield % | -183.43 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers